Viatris Expands RYZUMVI Indication with FDA Approval for Presbyopia…

Event summary

Viatris received FDA approval for RYZUMVI (phentolamine ophthalmic solution 0.75%) to treat presbyopia in adults on October 16, 2026.
RYZUMVI was previously approved for pharmacologically-induced mydriasis, making this a new indication.
Viatris is exploring partnerships to commercialize RYZUMVI for presbyopia in the U.S.
The product is developed under a global licensing agreement with Opus Genetics.

The big picture

Viatris' FDA approval for RYZUMVI in presbyopia expands its portfolio in the ophthalmology sector, a market driven by an aging population. The move aligns with broader industry trends toward developing treatments for age-related conditions. The strategic partnership with Opus Genetics underscores Viatris' focus on leveraging external innovation to drive growth.

What we're watching

Commercialization Strategy: Whether Viatris can secure a strong U.S. partner to maximize RYZUMVI's market potential in presbyopia.
Market Penetration: The pace at which RYZUMVI can capture market share in the presbyopia treatment space.
Regulatory Dynamics: How the FDA's approval process for new indications may impact future product expansions.